AC
CRXT

Ayrton Capital’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Ayrton Capital’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-32,525
Closed -$12K – 126
2022
Q2 		$12K Buy
+32,525
New +$22.8K 0.02% 81

Other funds holding CRXT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Ayrton Capital's CRXT Position: Q3 2022 in Review

Ayrton Capital sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 32,525 shares — an estimated $12K sold.

Ayrton Capital first reported a position in CRXT in Q2 2022 and held it in 1 quarter. The position peaked at $12K in Q2 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

  • Ayrton Capital reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Ayrton Capital sold 32,525 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $12K.
  • Ayrton Capital first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Ayrton Capital's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $12K in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Ayrton Capital's 13F filing for Q3 2022, filed 9 Nov 2022.